178 related articles for article (PubMed ID: 22545201)
1. Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A.
Tang L; Azzi J; Kwon M; Mounayar M; Tong R; Yin Q; Moore R; Skartsis N; Fan TM; Abdi R; Cheng J
J Transplant; 2012; 2012():896141. PubMed ID: 22545201
[TBL] [Abstract][Full Text] [Related]
2. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression.
Azzi J; Tang L; Moore R; Tong R; El Haddad N; Akiyoshi T; Mfarrej B; Yang S; Jurewicz M; Ichimura T; Lindeman N; Cheng J; Abdi R
FASEB J; 2010 Oct; 24(10):3927-38. PubMed ID: 20547662
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
4. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
Chan JM; Zhang L; Yuet KP; Liao G; Rhee JW; Langer R; Farokhzad OC
Biomaterials; 2009 Mar; 30(8):1627-34. PubMed ID: 19111339
[TBL] [Abstract][Full Text] [Related]
5. On the synthesis of mucus permeating nanocarriers.
Bourganis V; Karamanidou T; Samaridou E; Karidi K; Kammona O; Kiparissides C
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):239-49. PubMed ID: 25661586
[TBL] [Abstract][Full Text] [Related]
6. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.
Zhang CX; Cheng Y; Liu DZ; Liu M; Cui H; Zhang BL; Mei QB; Zhou SY
J Nanobiotechnology; 2019 Jan; 17(1):18. PubMed ID: 30683110
[TBL] [Abstract][Full Text] [Related]
7. Poly(D, L-lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and photototoxicity by surface PEG coating.
Boix-Garriga E; Acedo P; Casadó A; Villanueva A; Stockert JC; Cañete M; Mora M; Sagristá ML; Nonell S
Nanotechnology; 2015 Sep; 26(36):365104. PubMed ID: 26293792
[TBL] [Abstract][Full Text] [Related]
8. PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium.
Gholizadeh S; Kamps JAAM; Hennink WE; Kok RJ
Int J Pharm; 2018 Sep; 548(2):747-758. PubMed ID: 29042337
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
10. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.
Ankola DD; Battisti A; Solaro R; Kumar MN
J R Soc Interface; 2010 Aug; 7 Suppl 4(Suppl 4):S475-81. PubMed ID: 20504806
[TBL] [Abstract][Full Text] [Related]
12. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
14. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
15. New approach to treating spinal cord injury using PEG-TAT-modified, cyclosporine-A-loaded PLGA/polymeric liposomes.
Gao SJ; Liu Y; Wang HJ; Ban DX; Cheng SZ; Ning GZ; Wang LL; Chang J; Feng SQ
J Drug Target; 2017 Jan; 25(1):75-82. PubMed ID: 27250819
[TBL] [Abstract][Full Text] [Related]
16. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
17. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
El-Hammadi MM; Delgado ÁV; Melguizo C; Prados JC; Arias JL
Int J Pharm; 2017 Jan; 516(1-2):61-70. PubMed ID: 27825867
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of cyclosporine A/HPβCD-incorporated PLGA nanoparticles for development of effective ocular preparations.
Aksungur P; Demirbilek M; Denkbaş EB; Unlü N
J Microencapsul; 2012; 29(6):605-13. PubMed ID: 22432850
[TBL] [Abstract][Full Text] [Related]
20. Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Aβ
Amin FU; Shah SA; Badshah H; Khan M; Kim MO
J Nanobiotechnology; 2017 Feb; 15(1):12. PubMed ID: 28173812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
